Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CLRB with free AI briefings, catalyst countdowns, and dilution alerts.

CLRB · Cellectar Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$24.6M Cash on Hand
9.6mo Cash Runway
Follow CLRB by email Get an email when CLRB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CLRB, unsubscribe in one click. Privacy

📣 What CLRB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Glutathione Disulfide NOV-002 Non Small Cell Lung Cancer Phase 3 · NCT00347412 Completed
Iodine I 131 Iopofosine Waldenstrom Macroglobulinaemia Phase 3 · NCT07766421 Not yet recruiting
Cyclophosphamate Waldenstrom Macroglobulinaemia Phase 3 · NCT07766421 Not yet recruiting
Iodine I 124 Iopofosine Glioblastoma Phase 2 · NCT01898273 Terminated
NOV-205 Hepatitis C Phase 2 · NCT01058512 Completed
I124-NM404 Non Small Cell Lung Cancer Phase 1 · NCT00582283 Completed
Iodine I 125 Iopofosine Breast Cancer Phase 1 · NCT07311993 Recruiting

Also used in these trials (approved or third-party drugs, not CLRB's own candidates): Carboplatin, Rituximab, Paclitaxel, Dexamethasone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CLRB holds $24.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.7M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CLRB files for a raise →

👥 Who Owns CLRB

Insiders 1.4% Other 5%+ holders 2.5% Institutions 64.2% Public and other holders 31.9%
HolderTypeShares% of sharesAs of
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 944,265 9.41% 2026-09-30
Empery Asset Management, LP Institution (13G, 5%+) 864,090 8.61% 2026-06-30
Stonepine Capital Management, LLC Institution (13G, 5%+) 863,277 8.60% 2026-05-04
SilverArc Capital Management, LLC Institution (13G, 5%+) 851,285 8.48% 2026-06-30
StemPoint Capital LP Institution (13G, 5%+) 845,740 8.42% 2026-06-30
Bleichroeder LP Institution (13G, 5%+) 808,300 8.05% 2026-06-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 798,382 7.95% 2026-05-29
Caligan Partners LP Institution (13G, 5%+) 469,998 4.68% 2026-06-30
Rosalind Advisors, Inc. 5%+ holder (13G) 247,715 2.47% 2025-12-31
Andrei Shustov
Senior Vice President, Medical · +260,000 options
Insider 55,038 0.55% 2023-12-08
Darrell Shane Lea
Chief Commercial Officer · +360,000 options
Insider 39,599 0.39% 2023-06-23
Jarrod Longcor
Chief Operating Officer · +1.31M options
Insider 20,451 0.20% 2026-05-07

Share count 10,039,183 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CLRB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLRB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.